This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M05.0 | Special Copayment Reduction: V223 (severe intractable disease, 5 years) |
| B. Synonyms | Felty syndrome, splenomegaly and leukopenia RA |
| C. Adult onset | Adult onset very high — Felty syndrome presents almost without exception in adults (mainly in their 50s–70s). It occurs in patients with long-standing (mean 10–15 years) seropositive RA. |
| 1. History | See main text |
| 2. Causes | See main text |
| 3. Genetics | See main text |
| 4. General epidemiology | See main text |
| 5. Pathophysiology | See main text |
| 6. Symptoms | See main text |
| 7. Signs | See main text |
| 8. Screening | See main text |
| 9. Diagnosis | See main text |
| 10. Treatment | See main text |
| 11. Prognosis | See main text |
| 12. Prevention | See main text |
| 13. References | See main text |
Rheumatoid arthritis (RA) has been described for hundreds of years, and archaeological evidence includes reports of RA-specific joint damage in the skeletal remains of Native Americans. However, the clinical description of RA in Europe began in the 18th century. In 1800, the French physician Augustin Jacob Landré-Beauvais first described the clinical features of RA in detail, and in 1858 Alfred Baring Garrod of Britain formally introduced the name "rheumatoid arthritis."
In the early 20th century, RA diagnosis relied on clinical and radiological findings. With the discovery of rheumatoid factor (RF) in the 1940s, serological diagnosis became possible, and in 1959 the American Rheumatism Association (ARA) published the first diagnostic criteria (Rome criteria). These evolved into the 1961 ACR (then ARA) criteria, the revised 1987 ACR criteria, and the 2010 ACR/EULAR joint classification criteria. In the 2010 criteria, anti-cyclic citrullinated peptide antibodies (anti-CCP/ACPA) were added, increasing sensitivity for diagnosing early RA.
In the history of treatment, important turning points were gold salt treatment in the 19th century, the introduction of corticosteroids in the 1940s (Philip Hench and Edward Kendall, Nobel Prize 1950), and the introduction of methotrexate (MTX) in the 1970s–80s. The opening of the biologic era, beginning with infliximab (anti-TNF) in the late 1990s, transformed the paradigm of RA treatment. Subsequently, abatacept (CTLA4-Ig), rituximab (anti-CD20), tocilizumab (anti-IL-6R), and JAK inhibitors (tofacitinib, baricitinib, upadacitinib) were introduced, greatly expanding the treatment options for RA.
Felty syndrome was first named in 1924, when the American physician Augustus Roy Felty described 5 patients with splenomegaly, neutropenia, and arthritis. It was subsequently recognized as a severe complication or subtype of RA. Until the mid-20th century, splenectomy was the main treatment for Felty syndrome, but with the introduction of methotrexate (MTX) and anti-TNF agents in the 1980s–90s, the effectiveness of medical treatment was confirmed. Currently the incidence of Felty syndrome is decreasing owing to improved DMARD therapy.
The cause of rheumatoid arthritis is understood as a complex interaction of genetic predisposition, environmental factors, and immunological abnormalities.
The heritability of RA is estimated at about 50–60%. Alleles of the HLA-DRB1 gene encoding the "shared epitope" (DRB1*04:01, *04:04, *01:01, etc.) are the strongest genetic risk factor. The shared epitope is particularly strongly associated with anti-cyclic citrullinated peptide antibody (ACPA)-positive RA. Many non-HLA genes, such as PTPN22, PADI4, STAT4, CTLA4, IL-2RA, and CCR6, also contribute to RA susceptibility.
Smoking is the strongest environmental risk factor, inducing an immune response to citrullinated proteins and promoting ACPA production. Smoking RA is more severe and interacts with the HLA-DRB1 shared epitope. There is evidence that the protein citrullinating enzyme (PAD) of oral microbes (periodontal bacteria such as Porphyromonas gingivalis) may contribute to the development of ACPA. Studies associating gut microbial dysbiosis with the development of RA are increasing.
In ACPA (anti-CCP)-positive RA, autoantibodies to citrullinated proteins (vimentin, fibrinogen, α-enolase, type II collagen, etc.) form years before and precede clinical onset. These autoantibodies and RF (IgM anti-IgG) form immune complexes, which deposit in the joint synovium, activate complement, and promote joint inflammation.
In Felty syndrome, neutropenia arises mainly by two mechanisms. First, sequestration and destruction of neutrophils in the spleen are increased. Second, anti-neutrophil antibodies bind to neutrophil surface antigens (Fc receptors, NA1/NA2 antigens) and destroy neutrophils by targeting them. When an increase in large granular lymphocytes (LGL) accompanies, neutrophil cytotoxicity of T-LGL cells is also involved. There is a strong association with HLA-DR4 (DRB1*04:01), so genetic predisposition is important.
The genetic basis of rheumatoid arthritis has been extensively explored, and more than 100 susceptibility loci have been identified so far.
HLA region: Alleles of the HLA-DRB1 gene carrying the shared epitope (QKRAA/QRRAA/RRRAA) are the key genetic risk factor for ACPA-positive RA. HLA-DRB1*04:01 (DR4) shows the strongest association, and others such as *04:04, *04:05, *01:01, *01:02, and *10:01 are associated with increased RA risk. The shared epitope is located in the antigen-binding groove (P4 position) of the MHC class II molecule and is favorable for effectively presenting citrullinated peptides to autoreactive CD4+ T cells.
PTPN22: The R620W variant (rs2476601) of the PTPN22 gene, which encodes protein tyrosine phosphatase 22 (lymphoid tyrosine phosphatase, LYP), is strongly associated with ACPA-positive RA. The LYP R620W variant lowers the T-cell activation threshold and impairs peripheral deletion of autoreactive T cells.
PADI4: Variants of the PADI4 gene, which encodes the citrullinating enzyme (peptidylarginine deiminase 4, PAD4), are strongly associated with RA risk, especially in East Asians. An association between the PADI4 haplotype and ACPA positivity has been reported in Korean RA patients.
Other susceptibility genes include STAT4 (IL-12/IL-23 signaling), CTLA4 (T-cell costimulation), CCR6 (Th17 cell homing receptor), IL-2RA (regulatory T-cell function), TNFAIP3 (A20, regulation of TNF signaling), and FCGR2A (IgG Fc receptor).
Genetics specific to Felty syndrome: HLA-DRB1*04:01 (DR4) is observed at a high frequency of 70–90% in Felty syndrome, much higher than in ordinary RA (about 40–50%). This suggests that Felty syndrome is a strongly HLA-DR4-related autoimmune phenotype. In Felty syndrome with increased LGL (LGL Felty syndrome), activating variants of STAT3 and STAT5b have been reported.
Rheumatoid arthritis is a common autoimmune disease with a worldwide prevalence of about 0.5–1%. It occurs 2–3 times more often in women than in men, and the peak age of onset is the 40s–60s in women and the 60s–70s in men. The prevalence of RA in Korea is about 0.7–1%, and according to National Health Insurance Service data, about 250,000–300,000 people were receiving treatment as of 2020. The incidence of RA is 20–50 per 100,000 per year in the West and at a similar level in Korea.
If left untreated, RA causes joint destruction and functional disability, and life expectancy is reported to be shortened by 5–10 years compared with the general population because of systemic complications such as cardiovascular disease (atherosclerosis, myocardial infarction, stroke), pulmonary complications, infection, and malignancy (lymphoma). Since the introduction of biologics and JAK inhibitors, functional outcomes and mortality in RA patients have improved markedly.
Epidemiology of Felty syndrome: Felty syndrome occurs in about 0.5–3% of RA patients and always occurs in long-standing (mean 10–15 years) seropositive RA. Its incidence has been decreasing recently owing to improved DMARD therapy. It occurs mainly in women in their 50s–70s. It is more common in Caucasians and occurs more often in populations with a high frequency of HLA-DR4.
The pathophysiology of rheumatoid arthritis is described as a continuous process from the pre-clinical stage (pre-clinical RA) to clinical onset, chronic synovitis, and joint destruction.
ACPA and RF appear in the blood years before clinical RA onset. At this stage, citrullinated autoantigens are generated in tissues other than joints (lung, oral cavity, gut, etc.), and immune tolerance to them breaks down. The HLA-DRB1 shared epitope and environmental factors such as smoking and periodontal infection promote this process.
Autoantibody-antigen immune complexes deposit in the joint synovium, activate complement, and activate synovial macrophages via FcγR. CD4+ T cells (Th1, Th17), B cells, plasma cells, neutrophils, and dendritic cells infiltrate the synovium in large numbers, causing chronic synovial inflammation (synovitis) and pannus formation. TNF-α, IL-1β, IL-6, IL-17, and IL-21 are the main effector cytokines.
Osteoclasts are differentiated and activated by RANKL (receptor activator of NF-κB ligand) and M-CSF, causing bone erosion. Proteolytic enzymes such as MMPs (matrix metalloproteinases) and cathepsins B, D, and K degrade the cartilage matrix, causing cartilage loss. If chronic inflammation persists, joint space narrowing, bone deformity, and joint ankylosis progress.
Sequestration of neutrophils in the spleen, destruction of IgG-coated neutrophils by the monocyte-macrophage system, anti-neutrophil antibodies (anti-NA1/NA2, anti-Fc receptor), complement activation, and LGL cytotoxicity combine to cause neutropenia. Splenomegaly is immune-mediated splenic enlargement occurring without portal hypertension.
Symptoms of rheumatoid arthritis: Polyarticular symmetric arthritis (proximal interphalangeal joints of the fingers, metacarpophalangeal joints, wrists, elbows, knees, ankles), morning stiffness (1 hour or longer), joint swelling and tenderness, and rheumatoid nodules (subcutaneous nodules) appear. Severe joint destruction and functional decline may progress. Splenomegaly: accompanied by a feeling of fullness and pain in the left upper abdomen and early satiety. Symptoms related to neutropenia: recurrent infections (bacterial skin infection, pneumonia, urinary tract infection) occur. In severe neutropenia (ANC <500/μL), febrile neutropenia and life-threatening infection may occur.
On physical examination, splenomegaly (palpable spleen), findings of polyarthritis, rheumatoid nodules, and pallor (with anemia) are observed. On blood tests, neutropenia (ANC <2,000/μL, <500/μL in severe cases), thrombocytopenia (in some), anemia (anemia of chronic disease), a high RF titer (>1:640), ACPA positivity, serum ANA positivity (about 50%), and hypocomplementemia are found. Splenomegaly is confirmed on abdominal ultrasound or CT. On bone marrow biopsy, bone marrow cellularity is normal or increased (suggesting peripheral destruction).
Screening of the general population is not recommended. In the high-risk group of long-standing seropositive RA patients, neutropenia is detected early with regular CBC. During follow-up of RA patients, changes in spleen size are assessed (abdominal palpation, ultrasound if necessary). Felty syndrome is differentiated in RA patients who develop recurrent infections.
Diagnostic criteria: all three of RA (meeting the ACR/EULAR 2010 criteria), splenomegaly, and neutropenia (ANC <2,000/μL) must be met. Other causes of neutropenia (drug-induced, bone marrow infiltration, viral infection, primary autoimmune neutropenia) are excluded. The presence of LGL lymphocytosis (increased CD3+CD57+CD8+ cells) is checked. When bone biopsy is needed (to exclude aplasia when bone marrow cellularity is decreased), serum G-CSF concentration and anti-neutrophil antibodies are measured.
Underlying RA treatment: DMARD treatment including MTX is the basis. Anti-TNF agents (infliximab, etanercept, adalimumab) are effective for both RA and Felty syndrome. Rituximab (anti-CD20) has also been reported effective in Felty syndrome. Treatment of neutropenia: G-CSF (granulocyte colony-stimulating factor, filgrastim) is used to control neutropenia and recurrent infections. In severe recurrent infections, antimicrobial prophylaxis is considered. Splenectomy: In severe Felty syndrome refractory to DMARDs/G-CSF, splenectomy can temporarily restore neutrophil counts but has no effect on RA itself and relapse is common. Because the risk of infection with encapsulated organisms (pneumococcus, meningococcus, Haemophilus influenzae type b) increases after splenectomy, preoperative vaccination is essential.
Felty syndrome is a subtype of severe RA, and complications such as recurrent infection, splenic rupture, lower extremity skin ulcers, and increased risk of lymphoma may occur. Prognosis improves when RA and neutropenia are well controlled with DMARDs/biologics. Sepsis related to recurrent infection is the leading cause of death. The risk of lymphoma (especially diffuse large B-cell lymphoma) is higher than in ordinary RA, and regular monitoring is needed.
When RA is well controlled by early aggressive DMARD treatment, the development of Felty syndrome is prevented. With current treatment trends (early aggressive DMARDs, biologics), the occurrence of Felty syndrome is decreasing markedly. In patients with recurrent infections, regular monitoring of neutrophil counts, maintaining vaccinations such as pneumococcal and influenza, and oral hygiene care are important for infection prevention. After splenectomy, patients must be vaccinated against pneumococcus (PCV13, PPSV23), meningococcus, and Hib.